The drugmakers said an independent data and monitoring committee recommended stopping the trial due to the high efficacy rate. They plan to immediately seek emergency use authorization for the drug in the U.S. as well as authorization from other countries.
If authorized, the drug would be the fourth COVID-19 antibody drug authorized in the U.S., according to The New York Times.
A separate study showed the drug was also effective against virus variants discovered in the U.K., South Africa and Brazil, the drugmakers said in a news release.
The drug is being tested as an injection rather than an infusion, which would allow it to be given more easily, the Times reported. All currently authorized antibody drugs have to be administered through infusion.
The federal government hasn’t ordered any of GlaxoSmithKline and Vir Biotechnology’s antibody drug.
More articles on pharmacy:
US will purchase 100M more J&J vaccines
Very few severe allergic reactions tied to mRNA vaccines, research shows
Pfizer’s newest vaccine manufacturing site has history of mold, recall troubles
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.